{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:59:42Z","timestamp":1793401182526,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40123-025-01247-3","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T01:59:08Z","timestamp":1758765548000},"page":"2919-2936","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Aflibercept 8 mg versus Faricimab Treat-and-Extend for Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration: A Bayesian Fixed-Effect Network Meta-analysis of Clinical Trials"],"prefix":"10.1007","volume":"14","author":[{"given":"Scott M.","family":"Friedman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingxin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kuznik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Mojebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Keeping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore","family":"Leng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nimesh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"issue":"2","key":"1247_CR1","first-page":"e144","volume":"9","author":"GBD 2019 Blindness and Vision Impairment Collaborators","year":"2019","unstructured":"GBD 2019 Blindness and Vision Impairment Collaborators. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. Lancet Glob Health. 2019;9(2):e144\u201360.","journal-title":"Lancet Glob Health"},{"issue":"4","key":"1247_CR2","doi-asserted-by":"publisher","first-page":"687","DOI":"10.2337\/dc22-1834","volume":"46","author":"EA Lundeen","year":"2023","unstructured":"Lundeen EA, Kim M, Rein DB, et al. Trends in the prevalence and treatment of diabetic macular edema and vision-threatening diabetic retinopathy among commercially insured adults aged <65 years. Diabetes Care. 2023;46(4):687\u201396.","journal-title":"Diabetes Care"},{"issue":"12","key":"1247_CR3","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1001\/jamaophthalmol.2022.4401","volume":"140","author":"DB Rein","year":"2022","unstructured":"Rein DB, Wittenborn JS, Burke-Conte Z, et al. Prevalence of age-related macular degeneration in the US in 2019. JAMA Ophthalmol. 2022;140(12):1202\u20138.","journal-title":"JAMA Ophthalmol"},{"issue":"12","key":"1247_CR4","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/j.ophtha.2023.07.020","volume":"130","author":"JR Ehrlich","year":"2023","unstructured":"Ehrlich JR, Andes LJ, Eisenberg A, Saaddine J, Lundeen EA. Trends in the diagnosed prevalence and incidence of major eye diseases in Medicare Part B fee-for-service beneficiaries 68 years of age or older. Ophthalmology. 2023;130(12):1240\u20137.","journal-title":"Ophthalmology"},{"issue":"4","key":"1247_CR5","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1001\/jamaophthalmol.2022.0052","volume":"140","author":"EA Lundeen","year":"2022","unstructured":"Lundeen EA, Andes LJ, Rein DB, et al. Trends in prevalence and treatment of diabetic macular edema and vision-threatening diabetic retinopathy among Medicare part B fee-for-service beneficiaries. JAMA Ophthalmol. 2022;140(4):345\u201353.","journal-title":"JAMA Ophthalmol"},{"issue":"11","key":"1247_CR6","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1016\/j.ophtha.2014.05.006","volume":"121","author":"JF Korobelnik","year":"2014","unstructured":"Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121(11):2247\u201354.","journal-title":"Ophthalmology"},{"issue":"4","key":"1247_CR7","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","volume":"119","author":"QD Nguyen","year":"2012","unstructured":"Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789\u2013801.","journal-title":"Ophthalmology"},{"issue":"14","key":"1247_CR8","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419\u201331.","journal-title":"N Engl J Med"},{"issue":"14","key":"1247_CR9","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432\u201344.","journal-title":"N Engl J Med"},{"issue":"12","key":"1247_CR10","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537\u201348.","journal-title":"Ophthalmology"},{"issue":"4","key":"1247_CR11","doi-asserted-by":"publisher","first-page":"P1","DOI":"10.1016\/j.ophtha.2024.12.018","volume":"132","author":"GA Vemulakonda","year":"2025","unstructured":"Vemulakonda GA, Bailey ST, Kim SJ, et al. Age-related macular degeneration preferred practice pattern\u00ae. Ophthalmology. 2025;132(4):P1\u201374.","journal-title":"Ophthalmology"},{"issue":"4","key":"1247_CR12","doi-asserted-by":"publisher","first-page":"P75","DOI":"10.1016\/j.ophtha.2024.12.020","volume":"132","author":"JI Lim","year":"2025","unstructured":"Lim JI, Kim SJ, Bailey ST, et al. Diabetic retinopathy preferred practice pattern\u00ae. Ophthalmology. 2025;132(4):P75\u2013162.","journal-title":"Ophthalmology"},{"issue":"1","key":"1247_CR13","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1001\/jamaophthalmol.2019.4557","volume":"138","author":"K Mulligan","year":"2020","unstructured":"Mulligan K, Seabury SA, Dugel PU, Blim JF, Goldman DP, Humayun MS. Economic value of anti\u2013vascular endothelial growth factor treatment for patients with wet age-related macular degeneration in the United States. JAMA Ophthalmol. 2020;138(1):40\u20137.","journal-title":"JAMA Ophthalmol"},{"issue":"6","key":"1247_CR14","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.2337\/dc22-2527","volume":"46","author":"K Mulligan","year":"2023","unstructured":"Mulligan K, Kim J, Tysinger B, et al. The broader economic value of treatment for diabetic macular edema. Diabetes Care. 2023;46(6):1196\u2013203.","journal-title":"Diabetes Care"},{"key":"1247_CR15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2147\/OPTH.S151611","volume":"12","author":"C Ehlken","year":"2018","unstructured":"Ehlken C, Helms M, Bohringer D, Agostini HT, Stahl A. Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients. Clin Ophthalmol. 2018;12:13\u201320.","journal-title":"Clin Ophthalmol"},{"key":"1247_CR16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ajo.2018.04.010","volume":"191","author":"NM Holekamp","year":"2018","unstructured":"Holekamp NM, Campbell J, Almony A, et al. Vision outcomes following anti-vascular endothelial growth factor treatment of diabetic macular edema in clinical practice. Am J Ophthalmol. 2018;191:83\u201391.","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"1247_CR17","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","volume":"99","author":"FG Holz","year":"2015","unstructured":"Holz FG, Tadayoni R, Beatty S, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2015;99(2):220\u20136.","journal-title":"Br J Ophthalmol"},{"issue":"12","key":"1247_CR18","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.oret.2018.06.004","volume":"2","author":"TA Ciulla","year":"2018","unstructured":"Ciulla TA, Bracha P, Pollack J, Williams DF. Real-world outcomes of anti-vascular endothelial growth factor therapy in diabetic macular edema in the United States. Ophthalmol Retina. 2018;2(12):1179\u201387.","journal-title":"Ophthalmol Retina"},{"issue":"7","key":"1247_CR19","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.oret.2018.01.006","volume":"2","author":"TA Ciulla","year":"2018","unstructured":"Ciulla TA, Huang F, Westby K, Williams DF, Zaveri S, Patel SC. Real-world outcomes of anti-vascular endothelial growth factor therapy in neovascular age-related macular degeneration in the United States. Ophthalmol Retina. 2018;2(7):645\u201353.","journal-title":"Ophthalmol Retina"},{"issue":"1","key":"1247_CR20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.oret.2019.05.017","volume":"4","author":"TA Ciulla","year":"2020","unstructured":"Ciulla TA, Hussain RM, Pollack JS, Williams DF. Visual acuity outcomes and anti-vascular endothelial growth factor therapy intensity in neovascular age-related macular degeneration patients: a real-world analysis of 49 485 eyes. Ophthalmol Retina. 2020;4(1):19\u201330.","journal-title":"Ophthalmol Retina"},{"issue":"9","key":"1247_CR21","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.oret.2022.03.021","volume":"6","author":"TA Ciulla","year":"2022","unstructured":"Ciulla TA, Hussain RM, Taraborelli D, Pollack JS, Williams DF. Longer-term anti-VEGF therapy outcomes in neovascular age-related macular degeneration, diabetic macular edema, and vein occlusion-related macular edema: clinical outcomes in 130 247 eyes. Ophthalmol Retina. 2022;6(9):796\u2013806.","journal-title":"Ophthalmol Retina"},{"issue":"2","key":"1247_CR22","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1136\/bjophthalmol-2020-315933","volume":"105","author":"TA Ciulla","year":"2020","unstructured":"Ciulla TA, Pollack JS, Williams DF. Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28 658 patient eyes. Br J Ophthalmol. 2020;105(2):216\u201321.","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"1247_CR23","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.ajo.2015.06.023","volume":"160","author":"JL Prenner","year":"2015","unstructured":"Prenner JL, Halperin LS, Rycroft C, Hogue S, Williams Liu Z, Seibert R. Disease burden in the treatment of age-related macular degeneration: findings from a time-and-motion study. Am J Ophthalmol. 2015;160(4):725\u201331.","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"1247_CR24","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1007\/s00592-020-01513-9","volume":"57","author":"F Fajnkuchen","year":"2020","unstructured":"Fajnkuchen F, Delyfer MN, Conrath J, et al. Expectations and fears of patients with diabetes and macular edema treated by intravitreal injections. Acta Diabetol. 2020;57(9):1081\u201391.","journal-title":"Acta Diabetol"},{"key":"1247_CR25","doi-asserted-by":"publisher","first-page":"939","DOI":"10.2147\/OPTH.S100168","volume":"10","author":"S Sivaprasad","year":"2016","unstructured":"Sivaprasad S, Oyetunde S. Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion. Clin Ophthalmol. 2016;10:939\u201346.","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"1247_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2020-000669","volume":"6","author":"CK McClard","year":"2021","unstructured":"McClard CK, Wang R, Windham V, et al. Questionnaire to assess life impact of treatment by intravitreal injections (QUALITII): development of a patient-reported measure to assess treatment burden of repeat intravitreal injections. BMJ Open Ophthalmol. 2021;6(1):e000669.","journal-title":"BMJ Open Ophthalmol"},{"issue":"3","key":"1247_CR27","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1007\/s12325-022-02052-1","volume":"39","author":"A Kato","year":"2022","unstructured":"Kato A, Yasukawa T, Sugita I, et al. Mental status and feasibility of an intravitreal ranibizumab treat-and-extend regimen in patients with neovascular age-related macular degeneration. Adv Ther. 2022;39(3):1403\u201316.","journal-title":"Adv Ther"},{"issue":"1","key":"1247_CR28","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1159\/000540390","volume":"67","author":"F Viola","year":"2024","unstructured":"Viola F, Chi GC, Holekamp NM, et al. Caregiver experience survey of anti-vascular endothelial growth factor treatment for diabetic macular edema and neovascular age-related macular degeneration. Ophthalmic Res. 2024;67(1):516\u201327.","journal-title":"Ophthalmic Res"},{"issue":"10432","key":"1247_CR29","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/S0140-6736(23)02577-1","volume":"403","author":"DM Brown","year":"2024","unstructured":"Brown DM, Boyer DS, Do DV, et al. Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2\/3 trial. Lancet. 2024;403(10432):1153\u201363.","journal-title":"Lancet"},{"issue":"10432","key":"1247_CR30","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","volume":"403","author":"P Lanzetta","year":"2024","unstructured":"Lanzetta P, Korobelnik JF, Heier JS, et al. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet. 2024;403(10432):1141\u201352.","journal-title":"Lancet"},{"issue":"10326","key":"1247_CR31","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399(10326):729\u201340.","journal-title":"Lancet"},{"issue":"10326","key":"1247_CR32","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","volume":"399","author":"CC Wykoff","year":"2022","unstructured":"Wykoff CC, Abreu F, Adamis AP, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022;399(10326):741\u201355.","journal-title":"Lancet"},{"key":"1247_CR33","unstructured":"US Food and Drug Administration. EYLEA\u00ae HD (aflibercept) injection, for intravitreal use [package insert]. Regeneron Pharmaceuticals, Inc. Last updated October 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761355s006lbl.pdf. Accessed Feb 6, 2025."},{"key":"1247_CR34","unstructured":"Do DV. Aflibercept 8 mg for diabetic macular edema: 96-week results from the phase 2\/3 PHOTON trial. American Academy of Ophthalmology (AAO) Conference; November 3\u20136, 2023, 2023; San Francisco, CA."},{"key":"1247_CR35","unstructured":"Korobelnik JF. Aflibercept 8 mg in patients with neovascular age-related macular degeneration: phase 3 PULSAR trial 96-week results. American Academy of Ophthalmology Conference; November 3\u20136, 2023; San Francisco, CA."},{"key":"1247_CR36","unstructured":"US Food and Drug Administration. VABYSMO\u00ae (faricimab-svoa) injection, for intravitreal use [package insert]. Genentech, Inc. Last updated July 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761235s005lbl.pdf. Accessed Feb 6, 2025."},{"issue":"6","key":"1247_CR37","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.ophtha.2023.12.026","volume":"131","author":"TY Wong","year":"2024","unstructured":"Wong TY, Haskova Z, Asik K, et al. Faricimab treat-and-extend for diabetic macular edema: two-year results from the randomized Phase 3 YOSEMITE and RHINE trials. Ophthalmology. 2024;131(6):708\u201323.","journal-title":"Ophthalmology"},{"issue":"8","key":"1247_CR38","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","volume":"131","author":"AM Khanani","year":"2024","unstructured":"Khanani AM, Kotecha A, Chang A, et al. TENAYA and LUCERNE: two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2. Ophthalmology. 2024;131(8):914\u201326.","journal-title":"Ophthalmology"},{"key":"1247_CR39","unstructured":"European Medicines Agency. Eylea: EPAR - Product Information. 2012. Last updated Nov 29, 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/eylea-epar-product-information_en.pdf. Accessed Feb 19, 2025."},{"key":"1247_CR40","unstructured":"European Medicines Agency. Vabysmo: EPAR - Product Information. 2022. Last updated February 5, 2025. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vabysmo-epar-product-information_en.pdf. Accessed Feb 19, 2025."},{"issue":"5","key":"1247_CR41","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1177\/0272989X12458724","volume":"33","author":"S Dias","year":"2013","unstructured":"Dias S, Sutton AJ, Ades AE, Welton NJ. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making. 2013;33(5):607\u201317.","journal-title":"Med Decis Making"},{"key":"1247_CR42","unstructured":"Dias S, Sutton AJ, Welton NJ, Ades AE. NICE DSU technical support document 3: heterogeneity: subgroups, meta-regression, bias and bias-adjustment. 2011. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK395886\/pdf\/Bookshelf_NBK395886.pdf. Accessed Feb 13, 2025."},{"issue":"7\u20138","key":"1247_CR43","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/sim.3767","volume":"29","author":"S Dias","year":"2010","unstructured":"Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Stat Med. 2010;29(7\u20138):932\u201344.","journal-title":"Stat Med"},{"issue":"4","key":"1247_CR44","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.jval.2011.01.011","volume":"14","author":"DC Hoaglin","year":"2011","unstructured":"Hoaglin DC, Hawkins N, Jansen JP, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR task force on indirect treatment comparisons good research practices: part 2. Value Health. 2011;14(4):429\u201337.","journal-title":"Value Health"},{"key":"1247_CR45","unstructured":"Higgins J, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions version 5.1.0. Last updated March 2011. https:\/\/handbook-5-1.cochrane.org\/. Accessed Feb 13, 2025."},{"issue":"7414","key":"1247_CR46","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360.","journal-title":"BMJ"},{"key":"1247_CR47","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovic J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"1247_CR48","unstructured":"Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU technical support document 2: a generalised linear modelling framework for pair-wise and network meta-analysis of randomised controlled trials. 2011. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK310366\/pdf\/Bookshelf_NBK310366.pdf. Accessed Feb 13, 2025."},{"issue":"4","key":"1247_CR49","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/jrsm.1054","volume":"3","author":"G van Valkenhoef","year":"2012","unstructured":"van Valkenhoef G, Lu G, de Brock B, Hillege H, Ades AE, Welton NJ. Automating network meta-analysis. Res Synth Methods. 2012;3(4):285\u201399.","journal-title":"Res Synth Methods"},{"key":"1247_CR50","unstructured":"The R Foundation. R: A language and environment for statistical computing version 4.4.1. https:\/\/www.r-project.org\/. Accessed Jan 17, 2025."},{"issue":"4","key":"1247_CR51","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s40123-025-01098-y","volume":"14","author":"P Wojciechowski","year":"2025","unstructured":"Wojciechowski P, Wdowiak M, Panek M, et al. Efficacy, safety, and injection frequency with novel aflibercept 8 mg in neovascular age-related macular degeneration: a comparison with existing anti-VEGF regimens using a Bayesian network meta-analysis. Ophthalmol Ther. 2025;14(4):733\u201353.","journal-title":"Ophthalmol Ther"},{"key":"1247_CR52","doi-asserted-by":"publisher","first-page":"4273","DOI":"10.2147\/OPTH.S384995","volume":"16","author":"EA Meer","year":"2022","unstructured":"Meer EA, Oh DH, Brodie FL. Time and distance cost of longer acting anti-VEGF therapies for macular degeneration: contributions to drug cost comparisons. Clin Ophthalmol. 2022;16:4273\u20139.","journal-title":"Clin Ophthalmol"},{"issue":"6","key":"1247_CR53","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","volume":"50","author":"HC Bucher","year":"1997","unstructured":"Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50(6):683\u201391.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"1247_CR54","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11739-016-1583-7","volume":"12","author":"B Rouse","year":"2017","unstructured":"Rouse B, Chaimani A, Li T. Network meta-analysis: an introduction for clinicians. Intern Emerg Med. 2017;12(1):103\u201311.","journal-title":"Intern Emerg Med"},{"issue":"6","key":"1247_CR55","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1093\/ndt\/gfw092","volume":"31","author":"TM Esterhuizen","year":"2016","unstructured":"Esterhuizen TM, Thabane L. Con: meta-analysis: some key limitations and potential solutions. Nephrol Dial Transplant. 2016;31(6):882\u20135.","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"1247_CR56","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1001\/jamaophthalmol.2014.1698","volume":"132","author":"SB Bressler","year":"2014","unstructured":"Diabetic Retinopathy Clinical Research Network Writing Committee, Bressler SB, Edwards AR, et al. Reproducibility of spectral-domain optical coherence tomography retinal thickness measurements and conversion to equivalent time-domain metrics in diabetic macular edema. JAMA Ophthalmol. 2014;132(9):1113\u201322.","journal-title":"JAMA Ophthalmol"},{"issue":"8","key":"1247_CR57","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1097\/IAE.0000000000003194","volume":"41","author":"PK Kaiser","year":"2021","unstructured":"Kaiser PK, Wykoff CC, Singh RP, et al. Retinal fluid and thickness as measures of disease activity in neovascular age-related macular degeneration. Retina. 2021;41(8):1579\u201386.","journal-title":"Retina"}],"updated-by":[{"DOI":"10.1007\/s40123-026-01377-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T00:00:00Z","timestamp":1775260800000}}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01247-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-025-01247-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01247-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T10:01:54Z","timestamp":1783764114000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-025-01247-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":57,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1247"],"URL":"https:\/\/doi.org\/10.1007\/s40123-025-01247-3","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]},"assertion":[{"value":"7 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The  original online version of this article was revised due to figure 2 was incorrectly published. Now, the figure 2 has been corrected.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40123-026-01377-2","URL":"https:\/\/doi.org\/10.1007\/s40123-026-01377-2","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Scott Friedman has received grants or contracts from Bayer, JAEB Center, Ophthea, Regeneron Pharmaceuticals, Inc., Genentech, Amgen, Clearside Biomedical, EyePoint, ONL Therapeutics, REGENXBIO, Kowa, Kodiak Sciences, and Belite Bio, has participated on a Data Safety Monitoring Board or Advisory Board for Amgen, Genentech, and Ocular Therapeutics, and has stock or stock options in REvOpsis. Yingxin Xu, Andreas Kuznik, and Steven Sherman are employees and stockholders of Regeneron Pharmaceuticals, Inc. Ali Mojebi, Sam Keeping, and Keith Chan are employees of Precision AQ, which received funding from Regeneron Pharmaceuticals, Inc. for conducting this analysis. Theodore Leng has received funding from Astellas and served as a consultant for Astellas, Boehringer Ingelheim, Roche\/Genentech, Topcon, Toku, and Virtual Field. Nimesh Patel has served as an advisor for Alcon, Alimera, Allergan, Apellis, Biogen, DORC, EyePoint, Genentech, Kyoto Drug Company, Regeneron Pharmaceuticals, Inc., and REGENXBIO.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This NMA uses data from previously conducted clinical trials and does not report any new data from trials conducted in human participants by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}